Bone delivery conjugates and method of using same to target proteins to bone

ABSTRACT

A bone delivery conjugate having a structure selected from the group consisting of: A) X-D n -Y-protein-Z; and B) Z-protein-Y-D n -X, wherein X is absent or is an amino acid sequence of at least one amino acid; Y is absent or is an amino acid sequence of at least one amino acid; Z is absent or is an amino acid sequence of at least one amino acid; and D n  is a poly aspartate wherein n=10 to 16. Compositions comprising same and methods of use thereof.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.11/111,664, filed Apr. 21, 2005, which claims the benefit of the filingdates of U.S. Provisional Application Nos. 60/563,828 filed Apr. 21,2004, 60/590,347 filed Jul. 23, 2004, and 60/614,984 filed Oct. 4, 2004,each of which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to bone delivery conjugates and method ofusing same to target proteins to bone. More specifically, the presentinvention relates to bone delivery compositions comprising peptidemotifs, engineered within the structure of a protein through recombinantDNA technology to promote binding to bone matrix.

BACKGROUND OF THE INVENTION

Technological advances in molecular biology, recombinant proteinproduction and large scale protein purification have allowed theproduction of large amounts of proteins now used as biopharmaceuticals.For example, monoclonal antibodies and soluble forms of the TNF-areceptor have been used in the treatment of autoimmune diseases such asCrohn's disease or severe forms of psoriasis (1). Another example of useof recombinant protein is enzyme replacement therapy (ERT). ERT has beenused to treat lysosomal storage diseases. This group of geneticdisorders is characterized by the loss of function of lysosome enzymesresulting in severe somatic, and sometimes neuronal, pathologies. In ERTfor these diseases, the patients are infused with large doses of normalenzymes. These infused enzymes are then internalized from circulationvia cell surface receptors (mannose-6 phosphate receptor) and enter theendocytic pathway on their way to their site of action, the lysosome.Not all attempts to treat genetic disorders through ERT have beensuccessful.

Hypophosphatasia is a rare, heritable type of rickets or osteomalaciathat occurs with an incidence of 1 per 100,000 births for the moresevere form of the disease. Milder forms are more prevalent. In thisinborn metabolism defect, mutations inactivate the gene that encodes thetissue-nonspecific isoenzyme of alkaline phosphatase. It ischaracterized biochemically by subnormal alkaline phosphatase activityin serum. Alkaline phosphatase deficiency in osteoblasts andchondrocytes impairs skeletal mineralization, leading to rickets orosteomalacia.

There is a very broad range of expressivity of hypophosphatasia,spanning from a perinatal form often causing stillbirth from anunmineralized skeleton, to a milder form featuring only premature lossof teeth. Severely affected infants and children inherithypophosphatasia as an autosomal recessive trait. There are four mainforms of the disease: perinatal, infantile, childhood and adult.Perinatal hypophosphatasia manifests during gestation and most affectednewborns survive only briefly. Infantile hypophosphatasia becomesclinically apparent before 6 months of age. About 50% of patients diewithin a year. Childhood hypophosphatasia varies greatly in severity butmost of these patients will suffer from skeletal symptoms throughouttheir life. Adult hypophosphatasia appears during middle age, withsymptoms such as painful recurrent stress fractures having poor healing.

Osteoblasts and chondrocytes are normally rich in tissue-nonspecificalkaline phosphatase where it is attached to the cell surface. Inhypophosphatasia, the lack of alkaline phosphatase activity results inthe extracellular accumulation of three phosphorus-compounds believed tobe substrates of the enzyme: phosphoethanolamine (PEA), inorganicpyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). PPi is aninhibitor of hydroxyapatite crystal growth, and PPi build-up in thedisease accounts for the impaired skeletal mineralization. Consequently,providing active enzyme to patients suffering from hypophosphatasia willdecrease extracellular PPi levels and improve skeletal mineralization.

Currently, there is no established medical therapy for hypophosphatasia.Trials of enzyme replacement using intravenous infusions of alkalinephosphatase have failed. It appears that alkaline phosphatase activitymust be increased not in circulation but in the skeleton itself. Thishypothesis was confirmed recently by bone marrow transplantation.Unfortunately, the benefits of the transplantation lasted only for ashort period of time due to poor engraftment.

There is a therefore a need to provide enzyme replacement therapyapproach to provide active enzyme to the skeleton of patients sufferingfrom hypophosphatasia.

Bone-targeted proteins could be useful not only for the treatment orprevention of hypophosphatasia (loss of function of alkalinephosphatase) but also for the treatment or prevention of other geneticdiseases characterized by defective enzymatic activity involved in bonemetabolism, such as X-linked hypophosphatemic rickets (XLH) (loss offunction of phosphate regulating gene with homology to endopeptidases onthe X chromosome (PHEX)).

XLH is the most prevalent of the familial hypophosphatemias (OMIM307800, 307810). It is characterized by reduced phosphate reuptake inthe kidney, hypophosphatemia, normocalcemia, normal to low plasma1,25-dihydroxyvitamin D3 (1,25(OH)₂D, calcitriol) levels, normalparathyroid gland function and elevated plasma alkaline phosphataseactivity. These changes are associated with growth retardation, lowerextremity deformity, radiologic and histomorphometric evidence ofrickets and osteomalacia. This disease appears to result from combinedrenal defects in tubular phosphate reabsorption and vitamin Dmetabolism, as well as a functional disorder in bone and teeth. XLHresults from inactivating mutations in the PHEX gene, a member of thezinc metallopeptidase family of type II integral membrane glycoproteins.These mutations prevent the expression of a functional PHEX enzyme atthe cell surface of osteoblasts. As of now, treatment of XLH patients isrestricted to supplementation with oral inorganic phosphate (Pi)supplements in four or five divided doses per day, and co-administrationof 1,25(OH)₂D to compensate for the inappropriate synthesis of1,25(OH)₂D. Such high doses of phosphate frequently causegastrointestinal intolerances, particularly diarrhea, leading to patientnon-compliance. On the one hand, the phosphate load carries the risk ofprovoking secondary hyperparathyroidism (which may be severe enough tonecessitate parathyroidectomy) while on the other hand, administrationof excess 1,25(OH)₂D may lead to hypercalciuria, hypercalcemia andnephrocalcinosis.

Useful ERT for XLH would therefore seek to replace the defective PHEXenzyme in XLH patients with a functional enzyme obtained throughrecombinant DNA technology. As the normal PHEX enzyme is anchored inosteoblast plasma membrane by a hydrophobic peptide, the natural form ofPHEX cannot be produced and purified in sufficient quantities to be usedin a pharmaceutical preparation. To circumvent the problem, a solubleform of recombinant PHEX (or sPHEX) was engineered and produced in cellcultures, purified and formulated for intravenous (IV) administration(WO 00/50580). sPHEX was then injected in Hyp mice, a mouse model forXLH, as described in co-pending U.S. application Ser. No. 10/362,259.Improvement of several bone related serum parameter were observedincluding a reduction of the abnormally high levels of serum alkalinephosphatase. Although these experiments were successful, it was believedthat the efficacy of therapeutic sPHEX might be enhanced if therecombinant protein was modified so as to promote its binding to boneminerals.

There is therefore a need for means to successfully target proteins tobone matrix.

Biphosphonates are known to present high affinity binding tohydroxyapatite (HA), and has been used to target small molecules (4) andproteins (5) to bones. However this strategy requires chemicalmodifications of the purified proteins, and presents severaldisadvantages including possible interference with protein activity andadditional purification steps.

Another strategy to target small molecules to bone has been to conjugatethese entities to acidic peptides such as poly-Asp (6). This strategywas developed after the observation that several proteins synthesized byosteoblasts, the bone forming cells, bind to bone matrix throughsequences particularly rich in acidic amino acid residues (Asp and Glu).This is the case of osteopontin (7) and bone sialoprotein, twononcollagenous proteins. Hence acidic peptides (E₂₋₁₀ and D₂₋₁₀) wereused to target small molecules (i.e. methotrexate, FITC, Fmoc, biotin,estradiol) to hydroxyapatite in vitro. Acidic peptides (E₆ and D₆₋₁₀)were used to target small molecules (i.e. FITC, Fmoc, estradiol) tohydroxyapatite in vivo. Finally, E₆ was shown to confer to BSA,hemoglobin and IgG the ability to bind hydroxyapatite in vitro. In allthe above cases, linking of the acidic sequence was performedchemically.

The present invention seeks to meet these needs and other needs.

The present description refers to a number of documents, the content ofwhich is herein incorporated by reference in their entirety.

SUMMARY OF THE INVENTION

The present invention shows that large and complex molecules such asproteins can be fused with acidic peptides to successfully target bonein vivo.

According to a specific embodiment of the present invention there isprovided a bone delivery conjugate having a structure selected from thegroup consisting of: A) X-Dn-Y-protein-Z; and B) Z-protein-Y-Dn-X,wherein X is absent or is an amino acid sequence of at least one aminoacid; Y is absent or is an amino acid sequence of at least one aminoacid; Z is absent or is an amino acid sequence of at least one aminoacid; and Dn is a poly aspartate wherein n=10 to 16. In an otherspecific embodiment of the present invention, the protein in the bonedelivery conjugate is a soluble phosphate regulating gene with homologyto endopeptidases on the X chromosome (sPHEX). In an other specificembodiment of the present invention, the structure of the conjugate is:X-Dn-Y-sPHEX-Z. In other specific embodiment of the present invention,the sPHEX has a sequence selected from the group consisting of aminoacids 46 to 749 of FIGS. 10; 47 to 749 of FIGS. 10; 48 to 749 of FIGS.10; 49 to 749 of FIGS. 10; 50 to 749 of FIGS. 10; 51 to 749 of FIGS. 10;52 to 749 of FIGS. 10; 53 to 749 of FIGS. 10; and 54 to 749 of FIG. 10.In a specific embodiment of these bone delivery conjugates, n is 10. Inan other specific embodiment of this bone delivery conjugate, n is 11.In an other specific embodiment of this bone delivery conjugate, n is12. In an other specific embodiment of this bone delivery conjugate, nis 13. In an other specific embodiment of this bone delivery conjugate,n is 14. In an other specific embodiment of this bone deliveryconjugate, n is 15. In an other specific embodiment of this bonedelivery conjugate, n is 16. In a more specific embodiment of thepresent invention, the sPHEX consists of the sequence of amino acids 46to 749 of FIG. 10 and n=10.

In another specific embodiment of the present invention, the protein inthe conjugate is a soluble alkaline phosphatase (sALP). In an otherspecific embodiment, the structure of the conjugate is: Z-sALP-X-Dn-Y.In an other specific embodiment, sALP is encoded by the sequence as setforth in FIG. 16A. In an other specific embodiment, sALP has thesequence as set forth in FIG. 16B. In a specific embodiment of thesebone delivery conjugates, n is 10. In an other specific embodiment ofthis bone delivery conjugate, n is 11. In an other specific embodimentof this bone delivery conjugate, n is 12. In an other specificembodiment of this bone delivery conjugate, n is 13. In an otherspecific embodiment of this bone delivery conjugate, n is 14. In another specific embodiment of this bone delivery conjugate, n is 15. Inan other specific embodiment of this bone delivery conjugate, n is 16.In a more specific embodiment, n=10.

There is also provided an isolated nucleic acid molecule comprising apolynucleotide sequence selected from the group consisting of: apolynucleotide encoding a polypeptide comprising an amino acid sequenceas set forth in FIG. 8; a polynucleotide encoding a polypeptidecomprising an amino acid sequence as set forth in FIG. 11; apolynucleotide comprising the nucleotide sequence as set forth in FIG.7; a nucleotide sequence completely complementary to any of thenucleotide sequences in (a), (b) or (c); and a nucleotide sequence whichhybridizes under high stringency conditions to any of the nucleotidesequences in (a), (b), (c) or (d), wherein the high stringencyconditions comprise: pre-hybridization and hybridization in 6×SSC,5×Denhardt's reagent, 0.5% SDS and 100 mg/ml of denatured fragmentedsalmon sperm DNA at 68° C.; and washes in 2×SSC and 0.5% SDS at roomtemperature for 10 min; in 2×SSC and 0.1% SDS at room temperature for 10min; and in 0.1×SSC and 0.5% SDS at 65° C. three times for 5 minutes.

There is also provided a recombinant vector comprising said sequence.There is also provided a recombinant host cell comprising said vector.

There is also provided an isolated nucleic acid molecule comprising apolynucleotide sequence selected from the group consisting of: apolynucleotide comprising the nucleotide sequence as set forth in FIG.17A; a polynucleotide encoding a polypeptide comprising an amino acidsequence as set forth in FIG. 17B; a nucleotide sequence completelycomplementary to any of the nucleotide sequences in (a) or (b); and anucleotide sequence which hybridizes under high stringency conditions toany of the nucleotide sequences in (a), (b) or (c), wherein the highstringency conditions comprise: pre-hybridization and hybridization in6×SSC, 5×Denhardt's reagent, 0.5% SDS and 100 mg/ml of denaturedfragmented salmon sperm DNA at 68° C.; and washes in 2×SSC and 0.5% SDSat room temperature for 10 min; in 2×SSC and 0.1% SDS at roomtemperature for 10 min; and in 0.1×SSC and 0.5% SDS at 65° C. threetimes for 5 minutes.

There is also provided an isolated nucleic acid molecule encoding afunctional soluble PHEX comprising a polynucleotide sequence selectedfrom the group consisting of: a polynucleotide encoding a sPHEXcomprising amino acids 54 to 749 as set forth in FIG. 10; apolynucleotide encoding a sPHEX comprising amino acids 53 to 749 as setforth in FIG. 10; a polynucleotide encoding a sPHEX comprising aminoacids 52 to 749 as set forth in FIG. 10; a polynucleotide encoding asPHEX comprising amino acids 51 to 749 as set forth in FIG. 10; apolynucleotide encoding a sPHEX comprising amino acids 50 to 749 as setforth in FIG. 10; a polynucleotide encoding a sPHEX comprising aminoacids 49 to 749 as set forth in FIG. 10; a polynucleotide encoding asPHEX comprising amino acids 48 to 749 as set forth in FIG. 10; apolynucleotide encoding a sPHEX comprising amino acids 47 to 749 as setforth in FIG. 10; a polynucleotide encoding a sPHEX comprising aminoacids 46 to 749 as set forth in FIG. 10; a nucleotide sequencecompletely complementary to any of the nucleotide sequences in (a) to(i); and a nucleotide sequence which hybridizes under high stringencyconditions to any of the nucleotide sequences in (a) to (j), wherein thehigh stringency conditions comprise: pre-hybridization and hybridizationin 6×SSC, 5×Denhardt's reagent, 0.5% SDS and 100 mg/ml of denaturedfragmented salmon sperm DNA at 68° C.; and washes in 2×SSC and 0.5% SDSat room temperature for 10 min; in 2×SSC and 0.1% SDS at roomtemperature for 10 min; and in 0.1×SSC and 0.5% SDS at 65° C. threetimes for 5 minutes. In an other embodiment, the isolated nucleic acidmolecule further comprises at its 5′ end, a polynucleotide encoding apoly-aspartate selected from the group consisting of D₁₀ to D₁₆.

There is also provided an isolated sPHEX polypeptide comprising asequence selected from the group consisting of: amino acids 54 to 749 asset for in FIG. 10; amino acids 53 to 749 as set for in FIG. 10; aminoacids 52 to 749 as set for in FIG. 10; amino acids 51 to 749 as set forin FIG. 10; amino acids 50 to 749 as set for in FIG. 10; amino acids 49to 749 as set for in FIG. 10; amino acids 48 to 749 as set for in FIG.10; amino acids 47 to 749 as set for in FIG. 10; and amino acids 46 to749 as set for in FIG. 10.

There is also provided a bone delivery composition comprising a bonedelivery conjugate of the present invention, and a pharmaceuticallyacceptable carrier.

There is also provided a method of delivering a protein to bone tissueof a mammal comprising administering to said mammal an effective amountof a bone delivery conjugate as recited of the present invention.

There is also provided a method of delivering sPHEX to bone tissue of amammal comprising administering to said mammal an effective amount of abone delivery conjugate of the present invention.

There is also provided a method of delivering ALP to bone tissue of amammal in need thereof comprising administering to said mammal aneffective amount of a bone delivery conjugate of the present invention.

There is also provided a method of treating a condition or diseaserelated to a bone defect characterized by a lack of or an insufficientamount of functional phosphate regulating gene with homology toendopeptidases on the X chromosome (PHEX) comprising administering to amammal in need thereof a conjugate of the present invention, saidconjugate being in a pharmaceutically acceptable carrier. In specificembodiments, the condition or disease is X-linked hypophosphatemicrickets (XLH).

There is also provided a method of treating a condition or diseaserelated to a bone defect characterized by a lack of or an insufficientamount of functional alkaline phosphatase comprising administering to amammal in need thereof a conjugate of the present invention, saidconjugate being in a pharmaceutically acceptable carrier. In specificembodiments, the condition or disease is hypophosphatasia.

There is also provided a method of screening peptides for use in a bonedelivery protein-peptide conjugate comprising the steps of: fusing acandidate peptide to a reporter protein to form a protein-peptideconjugate; contacting the conjugate with bone tissue or mineral phase ofbone; and wherein the candidate peptide is selected when the presence ofthe reporter protein on bone tissue or mineral phase of bone is higherwhen it is conjugated with the candidate peptide than when it is not.

According to a specific embodiment of the present invention there isprovided a bone delivery conjugate of a protein fused to a peptideselected from the group consisting of deca-aspartate (D₁₀) tohexadeca-aspartate (D₁₆).

In specific embodiments of conjugates of the present invention, thesPHEX is fused at its N-terminal to D. In an other specific embodiment,the sPHEX is fused at its N-terminal to D₁₀. In an other specificembodiment, the sPHEX is fused at its N-terminal to D₁₂. In an otherspecific embodiment, the sPHEX is fused at its N-terminal to D₁₃. In another specific embodiment, the sPHEX is fused at its N-terminal to D₁₄.In an other specific embodiment, the sPHEX is fused at its N-terminal toD₁₅. In an other specific embodiment, the sPHEX is fused at itsN-terminal to D₁₆.

According specific embodiments of conjugates of the present invention,the sALP is fused at its C-terminal to D₁₀. In an other specificembodiment, the sALP is fused at its C-terminal b D₁₁. In an otherspecific embodiment, the sALP is fused at its C-terminal to D₁₂. In another specific embodiment, the sALP is fused at its C-terminal to D₁₃.In an other specific embodiment, the sALP is fused at its C-terminal toD₁₄. In an other specific embodiment, the sALP is fused at itsC-terminal to D₁₅. In an other specific embodiment, the sALP is fused atits C-terminal to D₁₆.

It is understood that any functional soluble protein may be used in theconjugate of the present invention. Although results for conjugatescomprising one specific sPHEX or sALP of the present invention arepresented herein, it is understood that any other functional sPHEX orsALP may be so used.

sPHEX

As used herein sPHEX means any soluble biologically active fragment ofPHEX or mutein thereof. Those of skill in the art may prepare expressionconstructs other than those expressly described herein for optimalproduction of sPHEX in suitable cell lines transfected therewith.Moreover, skilled artisans may design fragments of cDNA encoding solublebiologically active fragments and muteins of the naturally occurringPHEX which possess the same or similar biological activity to thenaturally occurring full-length enzyme.

To create a recombinant source for sPHEX, a large series of expressionvectors may be constructed and tested for expression of a PHEX cDNA.Based on transient transfection experiments, as well as stabletransfections, an expression construct may be identified that provides aparticularly high level of expression.

Without being so limited, any sPHEX comprising at least a native PHEXectodomain portion starting with the cysteine at position 54 of thesequence presented at FIG. 10 is encompassed by the present invention.

The conjugates according to specific embodiments of the presentinvention thus are any sPHEX comprising this 54-749 fragment of thenative PHEX, preferably the 53-749 native fragment, more preferably thenative 52-749 fragment, more preferably the native 51-749 fragment, morepreferably the 50-749 native fragment, more preferably the 49-749 nativefragment, more preferably the 48-749 native fragment, more preferablythe 47-749 native fragment, and more preferably the 46-749 nativefragment, along with a poly-aspartate selected from the group consistingof D₁₀ to D₁₅ fused immediately upstream of this fragment.

The conjugate may further optionally comprise one or more additionalamino acids 1) upstream from the poly-aspartate; and/or 2) between thepoly-aspartate and the native fragment or functional equivalent. Theseamino acids may be any amino acid. According to specific embodiments,they may be selected independently from the group consisting of anyamino acid except for cysteine, proline and tryptophan namely thoseamino acids known to induce disulfide bond formation or changes inconformation.

These amino acids may be present in the conjugate when for instance thecloning strategy used to produce it introduces them in these locations.

According to specific cloning strategies, amino acids located upstreamof the poly-aspartate in the recombinant cleavable PHEX can be selectedaccording to known parameters so as to provide an adequate substrate forspecific enzymes of the secretory pathway (e.g. furin or signalpeptidase) of the host cell that will be used to cleave the producedrecombinant cleavable PHEXs into a secreted bone targeting sPHEX. Thelikelihood of a designed sequence being cleaved by the signal peptidaseof the host cell can be predicted by an appropriate computer algorithmsuch as that described in Bendtsen et al. (J Mol Biol. 2004 Jul. 16;340(4):783-95) and available on the Web athttp://www.cbs.dtu.dk/services/SignalP/ which takes into accountparameters including the following: the amino acids at position −3 and−1 from the cleavage site by the signal peptidase desirably have smalland non charged side chains. Preferably, at position −1: Ala, Ser, Gly,Cys, Thr and occasionally Gln, Pro, and Leu. Similarly those at position−3 should preferably be: Ala, Ser, Gly, Cys, Thr, 11e, Leu, Val.Moreover, amino acids in position −6 and −4 from the cleavage site aredesirably those capable of inducing the formation of a beta-turn (suchas Pro) residues.

The present invention hence encompasses conjugates comprising additionalamino acids that may be selected on the basis of the cloning strategyused to produce a cleavable recombinant PHEX. Hence the cleavablerecombinant PHEX disclosed in Examples 3 and 4 below contains suchadditional amino acids upstream of the poly-aspartate and between thepoly-aspartate and the native ectodomain sequence. Also, the presentinvention encompasses a conjugate comprising the secPHEX disclosed inco-pending application no. WO 02/15918 prepared by fusing NL-1N-terminal fragment comprising a furin site to the PHEX nativeectodomain with the vector pcDNA3/RSV/NL-1-PHEX, and a secPHEXcomprising an immunoglobulin fragment at its N-terminal. Moreparticularly, FIG. 12 schematically presents the structure of secPHEXsthat comprise additional amino acids upstream of the native 46-749 PHEXectodomain fragment. Constructs no. 1 to 3 and 5 could be fused to apoly-aspartate and be used as conjugates of the present invention.Construct no. 4 constitutes a conjugate of the present invention: itcomprises a D₁₀ poly-aspartate and a native ectodomain fragment.

The conjugates of the present invention further also encompass sPHEXscomprising deletions at their C-terminal non detrimental to theirenzymatic activity.

Furthermore, the present invention comprises conjugates wherein thepoly-aspartate would be attached at the C-terminal of the native PHEXectodomain fragment.

sALP

ALP is a membrane-bound protein anchored through a glycolipid to itsC-terminal. This glycolipid anchor (GPI) is added post translationallyafter removal of a hydrophobic C-terminal end which serves both astransitional membrane anchor and as a signal for the addition of theGPI. Hence the sALP used in Example 6 herein is constituted of an ALPwherein the first amino acid of the hydrophobic C-terminal sequence,namely alanine, is replaced by a stop codon. The soluble ALP so formedcontains all amino acids of the native and thus active anchored form ofALP.

The sALP conjugates according to specific embodiments of the presentinvention thus are any sALP along with a poly-aspartate selected fromthe group consisting of D₁₀ to D₁₆ fused immediately downstream of thisfragment.

The conjugate may further optionally comprise one or more additionalamino acids 1) upstream from the poly-aspartate; and/or 2) between thepoly-aspartate and the native sALP fragment or functional equivalent.This is the case for instance when the cloning strategy used to producethe bone targeting conjugate introduces exogenous amino acids in theselocations. However the exogenous amino acids should be selected so asnot to provide an additional transamination site. The likelihood of adesigned sequence being cleaved by the transaminase of the host cell canbe predicted as described by Ikezawa (Biol Pharm. Bull. 2002, 25(4)409-417).

The conjugates of the present invention further also encompass sALPscomprising deletions at their N-terminal non detrimental to theirenzymatic activity.

Furthermore, the present invention comprises conjugates wherein thepoly-aspartate would be attached at the N-terminal of the native ALPanchored fragment or its biologically active fragment.

The term “recombinant protein” is used herein to refer to a proteinencoded by a genetically manipulated nucleic acid inserted into aprokaryotic or eukaryotic host cell. The nucleic acid is generallyplaced within a vector, such as a plasmid or virus, as appropriate forthe host cell. Although E. coli has been used as a host for expressingthe conjugates of the present invention in the Examples presentedherein, a person of ordinary skill in the art will understand that anumber of other hosts may be used to produce recombinant proteinsaccording to methods that are routine in the art. Representative methodsare disclosed in Maniatis, et al. Cold Springs Harbor Laboratory (1989).“Recombinant cleavable protein” as used herein is meant to refer to arecombinant protein that may be cleaved by a host's enzyme so as toproduce a secreted/soluble protein.

The term “ectodomain fragment” is meant herein when used in relation toPHEX is meant to refer to PHEX's fragment that is located outside of thecellular membrane when found in its native form.

The term “bone tissue” is used herein to refer to tissue synthesized byosteoblasts composed of an organic matrix containing mostly collagen andmineralized by the deposition of hydroxyapatite crystals.

The fusion proteins comprised in the bone delivery conjugates of thepresent invention are useful for therapeutic treatment of bone defectiveconditions by providing an effective amount of the fusion protein to thebone. The fusion protein is provided in the form of a pharmaceuticalcomposition in any standard pharmaceutically acceptable carrier, and isadministered by any standard procedure, for example by intravenousinjection.

The term “pharmaceutically acceptable carrier” is used herein to refer,when parenteral administration is elected as the route ofadministration, to pharmaceutically acceptable sterile aqueous ornon-aqueous solvents, suspensions or emulsions. Examples of non-aqueoussolvents are propylene glycol, polyethylene glycol, vegetable oil, fishoil, and injectable organic esters. Aqueous solvents include water;water-alcohol solutions; physiological saline; buffered medicalparenteral vehicles including sodium chloride solution, Ringer'sdextrose solution, dextrose plus sodium chloride solution, fluid andnutrient replenishers; electrolyte replenishers; Ringer's solutioncontaining lactose, or fixed oils.

The term “effective amount” is used herein to refer to the minimalamount of a pharmaceutical composition that should be administered to amammal in order to achieve a significant therapeutic effect. The dosageswill depend on many factors including the mode of administration.Typically, the amount of protein contained within a single dose will bean amount that effectively prevents, delays or treats bone relatedundesired condition without inducing significant toxicity. Inparticular, an effective amount of the conjugate and compositions of thepresent invention will comprise an amount of fusion protein which willcause a significant alleviation of clinical symptoms of the condition.

The effective amount may be given daily, weekly, monthly or fractionsthereof. Typically, a pharmaceutical composition of the invention can beadministered in an amount from about 0.001 mg up to about 500 mg per kgof body weight per day (e.g., 10 mg, 50 mg, 100 mg, or 250 mg). Dosagesmay be provided in either a single or multiple dosage regimen. Forexample, in some embodiments the effective amount is a dose that rangesfrom about 1 mg to about 25 grams of the conjugate to be targeted tobone per day, from about 50 mg to about 10 grams of the conjugate to betargeted to bone per day, from about 100 mg to about 5 grams of theconjugate to be targeted to bone per day, about 1 gram of the conjugateto be targeted to bone per day, about 1 mg to about 25 grams of theconjugate to be targeted to bone per week, about 50 mg to about 10 gramsof the conjugate to be targeted to bone per week, about 100 mg to about5 grams of the conjugate to be targeted to bone every other day, andabout 1 gram of the conjugate to be targeted to bone once a week.

These are simply guidelines since the actual dose must be carefullyselected and titrated by the attending physician based upon clinicalfactors unique to each patient. The optimal daily dose will bedetermined by methods known in the art and will be influenced by factorssuch as the age of the patient and other clinically relevant factors. Inaddition, patients may be taking medications for other diseases orconditions. The other medications may be continued during the time thatthe protein for delivery to bone is given to the patient, but it isparticularly advisable in such cases to begin with low doses todetermine if adverse side effects are experienced.

The term “high stringency conditions” are meant to refer to conditionsenabling sequences with a high homology to bind. Without being solimited, examples of such conditions are listed In the handbook“Molecular cloning, a laboratory manual, second edition of 1989 fromSambrook et al.: 6×SSC or 6×SSPE, Denhardt's reagent or not, 0.5% SDSand the temperature used for obtaining high stringency conditions ismost often in around 68° C. (see pages 9.47 to 9.55 of Sambrook) fornucleic acid of 300 to 1500 nucleotides. Although the optimaltemperature to be used for a specific nucleic acid probe may beempirically calculated, and although there is room for alternatives inthe buffer conditions selected, within these very well known conditionranges, the nucleic acid captured will not vary significantly. Indeed,Sambrook clearly indicates that the “choice depends to a large extent onpersonal preference” (see page 9.47). Sambrook specifies that theformula to calculate the optimal temperature which varies according tothe fraction of guanine and cytosine in the nucleic acid probe and thelength of the probe (10 to 20° C. lower than T_(m) wherein T_(m)=81.5°C.+16.6(log₁₀[Na⁺])+0.41(fraction G+C)−0.63 (% formamide−(600/l)) (seepages 9.50 and 9.51 of Sambrook).

Other objects, advantages and features of the present invention willbecome more apparent upon reading of the following non-restrictivedescription of preferred embodiments thereof, given by way of exampleonly with reference to the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

In the appended drawings:

FIG. 1 presents the purity status of GST and GST-D₁₀ proteins on an SDSpolyacrylamide gel after CL-4B chromatography;

FIG. 2 shows the promotion of GST binding to bone by D₆, D₁₀ and D₁₆peptide motifs through the percentage of the injected dose ofrecombinant GST found associated with specific tissues;

FIG. 3 provides a schematic representation of the plasmidpcDNA3-RSV-D₁₀sPHEX-NEO vector;

FIG. 4 presents a chromatographic profile of 280 nm detection of PHEXflow for the SP-Sepharose™ HP (A) and the blue-Sepharose HP (B).Straight line represents buffer ratio;

FIG. 5 presents a Sypro-Ruby™ stained SDS-PAGE analysis of the differentfractions collected throughout D₁₀sPHEX purification procedure;

FIG. 6 shows the variation in serum alkaline phosphatase levels (ALP)observed in Hyp mice injected daily with i.v. doses of sPHEX andD₁₀-sPHEX for 14 days. U/I values represent the decrease observedbetween day-3 (corresponding in the graphic to 0 U/I) and day 15 of theinjection regimen and are the mean of measures made on 6 animals;

FIG. 7 shows the nucleotide sequence of a recombinant DNA sequenceencoding a protein cleavable so as to produce D₁₀-sPHEX (SEQ ID NO: 1);

FIG. 8 shows the amino acid sequence encoded by the D₁₀-sPHEX of FIG. 7(SEQ ID NO: 2);

FIG. 9 compares the binding to the mineral phase of bone of proteins (A.GST B. sPHEX) with that of their deca-aspartate fused counterparts;

FIG. 10 shows the nucleotide sequence of a native (or membrane-bound)PHEX (SEQ ID NO: 3);

FIG. 11 shows the amino acid sequence (SEQ ID NO: 4) of a D₁₀-sPHEXconjugate produced by cleavage of the recombinant cleavable protein ofFIG. 8;

FIG. 12 schematically illustrates the structure and activities ofvarious secPHEX constructs;

FIG. 13 graphically illustrates through fluorimetric measurement of thealkaline phosphatase activity in the soluble cell extract and spentmedium of HEK293 transiently transfected with expression vectorsencoding sALP-D₁₀ and sALP;

FIG. 14 graphically illustrates the detection of sALP and sALP-D₁₀ byWestern blotting with the specific B4-78 antibody in the spent media andcell extract of HEK-293 after transient transfection. (Panel A: Ponceaured staining; Panel B: Blot a-B4-78). Shown on the left are the sizes ofthe molecular weight markers;

FIG. 15 graphically shows the binding to bone mineral phase of adeca-aspartate fused to secreted alkaline phosphatase;

FIG. 16 shows A. the nucleotidic sequence (SEQ ID NO: 5) of a solublealkaline phosphatase; and B. the amino acid sequence (SEQ ID NO: 6) ofthat soluble alkaline phosphatase;

FIG. 17 shows A. the nucleotidic sequence (SEQ ID NO: 7) encoding aconjugate of the present invention, namely sALP-D₁₀; and B. the aminoacid sequence (SEQ ID NO: 8) of that conjugate; and

FIG. 18 graphically shows the effect of D10-sALP on PPi-mediatedmineralization inhibition.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention showed that specific poly-aspartic peptides fusedin frame to a protein, as exemplified herein by thegluthatione-S-transferase protein (GST), used as a reporter protein, bysPHEX and by sALP, can significantly increase the bone binding capacityof these proteins.

The present invention is illustrated in further details by the followingnon-limiting examples.

Table 1 presents the sequence of oligonucleotides used in Examples 1 to7.

TABLE 1 SEQUENCE OF SYNTHETIC OLIGONUCLEOTIDES USED IN EXAMPLES 1 TO 7D₆ SEQ ID NO: 9. 5′-GATCCGATGACGATGACGATGACGC-3′ SEQ ID NO: 10.5′-GGCCGCGTCATCGTCATCGTCATCG-3′ D₁₀ SEQ ID NO: 11.5′-GATCCGATGACGATGACGATGACGATGACGATGACGC-3′ SEQ ID NO: 12.5′-GGCCGCGTCATCGTCATCGTCATCGTCATCGTCATCG-3′ D₁₆ SEQ ID NO: 13.5′-GATCCGATGACGATGACGATGACGATGACGATGACGATGACGATGACGATGACGC-3′ SEQ ID NO:14. 5′-GGCCGCGTCATCGTCATCGTCATCGTCATCGTCATCGTCATCGTCATCGTCATCG-3′ hMEPESEQ ID NO: 15.5′-GATCCGATGACAGTAGTGAGTCATCTGACAGTGGCAGTTCAAGTGAGAGCGATGGTGACGC-3′ SEQID NO: 16.5′-GGCCGCGTCACCATCGCTCTCACTTGAACTGCCACTGTCAGATGACTCACTACTGTCATCG-3′hStatherin SEQ ID NO: 17.5′-GATCCGATTCATCTGAAGAGAAATTTTTGCGTAGAATTGGAAGATTCGGTGC-3′ SEQ ID NO:18. 5′-GGCCGCACCGAATCTTCCAATTCTACGCAAAAATTTCTCTTCAGATGAATCG-3′ hMGP SEQID NO: 19.5′-GATCCTGTTATGAATCACATGAAAGCATGGAATCTTATGAACTTAATCCCTTCATTGC-3′ SEQ IDNO: 20. 5′-GGCCGCAATGAAGGGATTAAGTTCATAAGATTCCATGCTTTCATGTGATTCATAACAG-3′hOsteopontin SEQ ID NO: 21.5′-GATCCCAGAATGCTGTGTCCTCTGAAGAAACCAATGACTTTAAAGC-3′ SEQ ID NO: 22.5′-GGCCGCTTTAAAGTCATTGGTTTCTTCAGAGGACACAGCATTCTGG-3′ hBSP2 SEQ ID NO:23. 5′-GATCCGGCAGTAGTGACTCATCCGAAGAAAATGGAGATGACAGTTCAGAAGAGGAGGAGGAAGC- 3′ SEQID NO: 24.5′-GGCCGCTTCCTCCTCCTCTTCTGAACTGTCATCTCCATTTTCTTCGGATGAGTCACTACTGCCG- 3′hIGFBP5 SEQ ID NO: 25.5′-GATCCCGCAAAGGATTCTACAAGAGAAAGCAGTGCAAACCTTCCCGTGGCCGCAAGCGTGC-3′ SEQID NO: 26.5′-GGCCGCACGCTTGCGGCCACGGGAAGGTTTGCACTGCTTTCTCTTGTAGAATCCTTTGCGG-3′M81736 CBS SEQ ID NO: 27. 5′-AGTCGGGATCCGGAACAAGCAGCGTGTTCTAC-3′ SEQ IDNO: 28. 5′-AGATCGCGGCCGCTCAATTGTGCACGGTGTGATTAAAGG-3′ D₁₀ SEQ ID NO: 29.5′-CCGGAGATGACGATGACGATGACGATGACGATGACT-3′ SEQ ID NO: 30.3′-TCTACTGCTACTGCTACTGCTACTGCTACTGAGGCC-5′

Example 1 Bone Binding of GST-D₆, GST-D₁₀ and GST-D₁₆

Recombinant DNA technology was used to generate a plasmid containing anucleic acid encoding GST followed in frame by a nucleic acid encoding aD₆, D₁₀ or D₁₆ acidic peptide. To obtain the GST-D₆, GST-D₁₀ and GST-D₁₆conjugates, the oligonucleotide of SEQ ID NO:9 (see Table 1) was firstmixed with the oligonucleotide of SEQ ID NO:10, oligonucleotide of SEQID NO:11 mixed with oligonucleotide of SEQ ID NO:12, and oligonucleotideof SEQ ID NO:13 mixed with oligonucleotide of SEQ ID NO:14. Thisprocedure generated duplex oligonucleotides coding for D₆, D₁₀ and D₁₆,respectively, and having extremities compatible with cloning in thepGEX3T-4 plasmid (Pharmacia biotechnology) pre-digested with restrictionendonucleases BamHI and NotI. pGEX3T-4 vectors were transformed intoAP401 protease minus E. coli bacteria strain (lon::mini tetRara-Δlac-pro nalA argEam rifR thil [F′ pro AB lacIq Z M15]).

Positive bacterial colonies were used to seed a 10 ml pre-culture ofdouble YT media and 100 mg/litre ampicilin. Bacteria were grownovernight at 37° C. in an orbital shaker set at 250 rpm. The pre-culturewas added to 500 ml of fresh double YT ampicilin media in a 2 litresErlenmeyer flask. Bacteria were let to grow at 37° C. under orbitalshaking until a 595 nm optical density of 0.7 was reached. Proteinexpression was then induced by adding 500 μl of 0.1 M IPTG solution andthe bacteria put back to incubation for 2 hours. Bacteria were spun downat 8000×g for 10 minutes at 4° C. The pellet was suspended in 25 ml ofice-cold PBS containing Complete-EDTA caplet protease inhibitor(Boehringer Mannheim) and frozen at −20° C.

Bacteria cells were thawed and disrupted on ice with 6 pulses ofsonication every 50 seconds prior to centrifugation at 12000×g for 10minutes at 4° C. Supernatant was mixed with 500 μl of GS-4B wet resin(Amersham Pharmacia Biotech) equilibrated with PBS. The resin was keptas a suspension during the overnight incubation at 4° C. The resin wasrinsed with PBS until 280 nm optical density was below 0.01. Resin wasthen laid on an empty column and proteins eluted with 10 mM glutathionedissolved in PBS. The pooled elution fractions were dialyzed against 1mM sodium PO₄ pH 7.4 and 150 mM NaCl. Dialyzed proteins were filtered ina sterile environment on 0.22 μm PES membrane and kept at 4° C.Typically 40 and 60 mg of pure proteins were recovered per litre ofculture respectively. FIG. 1 shows an example of an SDS-PAGE analysis ofthe purified GST and GST-D₁₀. Purified proteins were iodinated usingIodo-Beads Iodination Reagent (Pierce).

GST and peptide-fused GST were dialyzed against PBS and concentrationset to 2 mg/ml. Iodination reaction was initiated by adding 2 PBS-rinsedIodo-Beads to 2 mCi of Na1251 (100 μCi/μl, ICN) dissolved in 500 μl ofPBS. Beads were incubated at room temperature for five minutes beforeadding 1 mg of dialyzed protein. The iodination reaction proceeded for15 minutes before the bead was removed and rinsed in 500 ml of PBS. Tothe final 1.5 ml of iodinated protein solution, 15 μl of 6 mM NaI wasadded to dilute non-specific radioactivity. The mixture was thendesalted using PD-10 gel filtration columns (Amersham Pharmacia Biotech)equilibrated with PBS. Proteins eluted in the void volume. They wereconcentrated and dialysed against the in vivo buffer (1 mM sodium PO4 pH7.4 and 150 mM NaCl) using Centriprep-YM10™ cartridges (Amicon).Radioactivity was measured using a gamma radiation counter, proteinconcentration was assessed by the Bradford assay and ¹²⁵I chemicallinkage to proteins was revealed by autoradiography of dried SDS-PAGE.Iodinated samples were kept at 4° C.

Bone Binding Ability of GST-Poly-Aspartic Peptides Fusion ProteinsCompared to that of GST Alone

The iodinated GST-fusion proteins were injected to mice under isofluraneanesthesia as an intravenous bolus through the subclavian vein. A doseof 1 mg of iodinated protein/per kg body weight was injected. Themaximum dose volume was set at 10 ml/kg. Duration of treatment was sixtyminutes. Ten and sixty minutes after injection, blood samples (0.1 to0.2 ml) were collected via the subclavian vein under anesthesia intoserum/gel clotting activator Microvette™ tubes (Sarstedt, #20.1291). Atnecropsy, blood samples were collected and animals were sacrificed byexsanguination from the heart under isoflurane anesthesia. Organs(kidneys, liver, femurs, tibias and thyroid) were collected, rinsed insaline 0.9% USP, blotted on gauze and transferred into gamma countertubes. Serum samples and organs were weighted and radioactivity wasmeasured. Results were expressed as percentage of injected dose. NeitherD₁₀-GST nor D₁₆-GST promoted binding to other organs than bone. Thisshowed the specificity of these conjugates to bone (Data not shown).

FIG. 2 shows that GST-D₆ fusion protein did not bind more to tibia orfemur than GST alone. In contrast, D₁₀ and D₁₆ peptide motifs promotedGST binding to bones.

The fact that D₆, a peptide shown to successfully deliver smallmolecules to bone could not successfully deliver a protein, namely GST,to bone shows that it is not predictable whether a specific acidicpeptide known to effectively deliver a small molecule to bone will alsobe effective in delivering a protein to bone.

Example 2 Binding Ability of GST Fused with Various Peptides

Human matrix extracellular phosphoglycoprotein (hMEPE) is a proteinsynthesized by osteoblasts that shows major similarities to a group ofbone and teeth mineral matrix phosphor-glycoproteins, proteins known tonaturally bind to bone matrix (8). Of particular importance, hMEPEpresents at its carboxy-terminus a sequence of 18 amino acid residues(DDSSESSDSGSSSESDGD) (SEQ ID NO: 31) similar to acidic peptides found indentin phosphorin and dentin sialophosphoprotein, both known to bind tobone matrix (8).

Human Statherin (hStatherin) is a protein synthesized by salivaryglands, which similarly to histatin directly modulates hydroxyapatitenucleation and/or growth. Of particular importance, hStatherin presentsa sequence of 15 amino acid residues at positions 20 to 34(DSSEEKFLRRIGRFG) (SEQ ID NO: 32) that was shown to bind tightly tohydroxyapatite (9).

Human Matrix Gla Protein (hMGP) is a protein synthesized by vascularsmooth muscle cells and chondrocytes that functions as an inhibitor ofhydroxyapatite polymerization by binding to crystal nuclei. Ofparticular importance, hMGP presents at its amino-terminus a sequence of17 amino acid residue at positions 19 to 35 of the open reading frame(CYESHESMESYELNPFI) (SEQ ID NO: 33) similar to phosphorylated gammacarboxyglutamic acidic peptides found in osteocalcin known to bind tobone matrix, and thought to promote binding to bone matrix (10).

Human osteopontin (hOPN) is a protein synthesized by osteoblasts thatregulates hydroxyapatite crystal growth. This protein belongs to thebone sialophosphoprotein family. Of particular importance, hOPN presentsa sequence of 13 amino acid residue (QNAVSSEETNDFK) (SEQ ID NO: 34) atpositions 58 to 70 of the open reading frame. This sequence shows a highlevel of homology among mammal species. Secondary structure predictionmakes this sequence appropriate to solvent exposure and this sequencewas shown to be phosphorylated at its serine residues. This lattercharacteristic is thought to affect binding to bone matrix (11).

Human Bone SialoProtein II (hBSP2) is a protein synthesized byosteoblasts that shows major similarities to a group of bone and teethmineral matrix phosphor-glycoproteins, proteins known to naturally bindto bone matrix. Of particular importance, hBSPII presents at itsamino-terminus a sequence of 18 amino acid residues at positions 62 to79 of the open reading frame (GSSDSSEENGDDSSEEEE) (SEQ ID NO: 35)similar to acidic peptides found in dentin phosphorin and MEPE, andthought to promote binding to bone matrix (8).

Human Insulin-like Growth Factor binding protein-5 (hIGFBP5) issynthesized by osteoblasts. This protein, similarly to proteins of theIGFBP family, is thought to regulate osteoblast function in the boneremodeling process. Of particular importance, hIGFBP5 presents asequence of 18 amino acid residues at positions 221 to 238 of the openreading frame (RKGFYKRKQCKPSRGRKR) (SEQ ID NO: 36) that was shown tobind tightly to hydroxyapatite (12).

Staphylococcus aureus collagen adhesin (M81736) is a protein expressedat the surface of S. aureus that promotes bacteria binding to collagenmatrix of mammalian bone and cartilageneous tissues. Such a binding wasreported to be instrumental in the development of pathogenesis such asosteomyelitis and infectious arthritis. Of particular importance, thecollagen binding domain (CBS) of this adhesin was reported to encompass151 amino acid residues (G168 to N318) of the open reading frame of theprotein (13, 14). The amino acid primary sequence being the following:

(SEQ ID NO: 37) GTSSVFYYKTGDMLPEDTTHVRWFLNINNEKSYVSKDITIKDQIQGGQQLDLSTLNINVTGTHSNYYSGQSAITDFEKAFPGSKITVDNTKNTIDVTIPQGYGSYNSFSINYKTKITNEQQKEFVNNSQAWYQEHGKEEVNGKSFNHTVH N.

Plasmids containing the acidic peptide sequences derived from hMEPE,hStatherin, hMGP, hOPN, hBSP2, hIGFBP5 and CBS following GST in framewere constructed to determine whether they could promote bone targetingof a recombinant protein. Recombinant DNA technology as described inExample 1 was used to generate plasmids for hMEPE, hStatherin, hMGP,hOPN, hBSP2 and hIGFBP5 derived peptides. The oligonucleotide pairsidentified in Table 1 for each of these peptides were mixed to obtainthe corresponding GST-acidic peptide fusion protein. This proceduregenerated duplex oligonucleotides coding for these acidic peptides andhaving extremities compatible with cloning in the pGEX3T-4 (Pharmaciabiotechnology) plasmid pre digested with restriction endonucleases BamHIand NotI.

A CBS-containing plasmid was constructed as follows. A synthetic genecorresponding to the CBS sequence was obtained from Bio S&T (Montreal)and inserted in plasmid pLIV Select. Oligonucleotides of SEQ ID NO: 27and 28 were used as primers in PCR reactions with plasmid pLIV Selectcontaining the CBS gene to amplify the CBS specific sequences. pGEX-4T-3vectors were transformed into AP401 protease minus E. coli bacteriastrain (lon::mini tetR ara-Δlac-pro nalA argEam rifR thil [F′ pro ABlacIq Z M15]).

Protein production and purification, and pharmacodistribution of theiodinated fusion protein were performed as described in Example 1.

None of these GST-acidic peptides was shown to bind to bones (result notshown).

The fact that the peptide derived from statherin, a peptide shown tosuccessfully deliver a small portion of osteopontin to bone, could notsuccessfully deliver the GST protein to bone shows that it is notpredictable whether a specific acidic peptide known to effectivelydeliver a small peptide to bone will also be effective in delivering aprotein to bone.

Example 3 D₁₀ Increases sPHEX's Ability to Correct Alkaline PhosphataseLevels in Mice

PHEX is a metallopeptidase that is widely believed to control the levelof bone peptide factors involved in the regulation of mineralization andkidney phosphate homeostasis. PHEX is expressed at the surface ofosteoblasts and osteocytes in contact with or imbedded in the bonematrix. This example provides data on the design, production andpurification of an extended form of sPHEX containing at its N-terminus asequence of 10 aspartic acid residues designed to anchor itself to thebone matrix.

D₁₀sPHEX Expression Vector

A BspEI endonuclease restriction site was inserted by site directedmutagenesis (QuickChange, Stratagene) into the pcDNA3-RSV-sPHEX-NEOvector (Boileau G. et al., Biochem. J. (2001) 355, 707-13) using thefollowing oligonucleotide primers:

(SEQ ID NO: 38) 5′- CAGTCAAGGTCTCTTATCCGGAAGTCTCCAAGCTAAACAGG-3′ and(SEQ ID NO: 39) 5′- CTGTTTAGCTTGGAGACTTCCGGATAAGAGACCTTGACTGG-3′.

The hexamer BspEI sequence (underlined) was inserted in frame with andupstream of the sPHEX DNA sequence. This construct encodes a recombinantprotein which is cleavable between the leucine and serine at positions41 and 42, respectively in FIG. 8. It is constituted therefore of twoexogenous amino acids, followed downstream by a deca-aspartate, which isin turn followed by two additional exogenous amino acids. These 4exogenous amino acids derive from the cloning strategy used to producethe conjugate. These exogenous amino acids were shown not to defeat theenzymatic activity of the conjugate (See FIG. 12 showing the specificactivity of this construct) but may be dispensed with. Downstream ofthese exogenous amino acids is an ectodomain fragment of the native PHEXstarting therefore with the serine at position 46 of the sequencepresented in FIG. 10. The modified pcDNA3-RSV-NEO vector was cleavedwith BspEI and then digested with alkaline phosphatase to remove the 5′phosphate moieties. An oligonucleotide duplex coding for deca-aspartate:[5′-CCGGAGATGACGATGACGATGACGATGACGATGACT-3′ (SEQ ID NO: 29) and3′-TCTACTGCTACTGCTACTGCTACTGCTACTGAGGCC-5′ (SEQ ID NO: 30)] was firstphosphorylated on its 5′ ends with T4 polynucleotide kinase and ligatedto the BspEI digested vector. This yielded the pcDNA3-RSV-D₁₀sPHEX-NEOvector (FIG. 3). This vector comprised the sequence presented in FIG. 7which encodes the recombinant cleavable PHEX having the amino acidsequence presented in FIG. 8.

Expression of Recombinant D₁₀sPHEX

To induce the stable expression of the D₁₀sPHEX protein, thepcDNA3-RSV-D₁₀sPHEX-NEO vector was transfected in LLC-PK1 cells (PorcineKidney cells; ATCC No. CRL-1392) using the Lipofectamine-Plus™ liposometransfection kit (Invitrogen). Transfected cells were selected by adding400 μg/ml G-418 (Life Technologies) to the medium. Clones of G-418resistant cells were screened for D₁₀sPHEX expression using the PHEXfluorescent enzymatic assay [Campos M. et al. Biochem. J. (2003) 373,271-9]. The apparent molecular weight of the protein recovered in thespent medium was estimated by immunoblotting using a monoclonal antibodyraised against a recombinant human PHEX fragment (K121-E294) asdescribed previously (Ruchon A F et al. J. Bone Miner. Res. (2000) 15,1440-1450). A G-418 resistant clone expressing 1 to 2 mg of D10sPHEX perlitre was used for protein production. Cells were seeded inCellstack-10™ (Corning) at a density of 7×10⁷ in 1.75 litres of media(199 media, 6% FBS, 1 mM NaPyruvate, Penicillin 1×10⁵ U/litre,Streptomycin 100 mg/litre and 1% G-418. D₁₀sPHEX expression wasincreased by incubating the cells in 1.75 litre of DMEM+10 mM sodiumbutyrate for four days at 37° C. and 5% CO₂ prior to harvest of thespent medium.

Purification and Characterization

Cell supernatant was centrifuged at 500×g for 5 minutes at 4° C. andfiltered on fiberglass (Fisher, APFC09050) and concentrated 10 to 40times using an Ultrasette™30 tangential flow filtration device (PallCanada). The pH of the solution was brought to 5.6 with 1 M acetic acidbefore an overnight dialysis at 4° C. against 50 mM sodium acetate, 100mM NaCl pH 5.6 (SP-buffer). The dialyzed supernatant was loaded, at aflow rate of 4 ml/min, on a 20 ml SulfoPropyl-Sepharose cation-exchangecolumn (Amersham Pharmacia Biotech) previously equilibrated withSP-buffer. The column was washed with the same buffer at the same flowrate until 280 nm absorbance baseline was reached. Most of thecontaminant proteins were then eluted with a 226 mM NaCl step in the SPbuffer. D₁₀sPHEX was then eluted with a 280 mM NaCl step (FIG. 4A).Fractions were analyzed by SDS-PAGE and with the PHEX enzymatic activityassay. Fractions containing sPHEX were pooled and extensively dialyzedagainst 20 mM MOPS pH 7, 250 mM NaCl prior to loading on a 5 mlBlue-Sepharose™ HP (Amersham Pharmacia) column at 5 ml/min. The columnwas rinsed, at the same flow rate with the same buffer and most of theD₁₀sPHEX protein was recovered by increasing the NaCl concentrationstepwise to 350 mM (FIG. 4B). Purity of the final fraction was greaterthan 95%. Alternatively, the Blue-Sepharose™ could be replaced byHeparin-Sepharose™ (Amersham Pharmacia) on which D₁₀sPHEX binds tightlyover a range of pH (5 to 8). D10sPHEX was eluted by using NaCl gradient.Purity was determined to be above 90%. D₁₀sPHEX was concentrated anddialyzed against 1 mM sodium PO4 pH 7.4, 150 mM NaCl usingCentriprep-50™ cartridges. Dialyzed sample was filtered in a sterileenvironment on 0.22 μm membrane. Purified D₁₀sPHEX was shown to remainstable over months at 4° C. Protein concentrations were determined usingthe Bradford method (DC protein assay kit; Biorad) with bovine serumalbumin (BSA) as a standard. Protein purity was assed by Sypro-Ruby™(Molecular Probes) staining of proteins resolved on SDS-PAGE 4-12% (FIG.3). D₁₀sPHEX enzymatic activity was determined using the fluorigenicsubstrate.

Effect of sPHEX and D₁₀-sPHEX Injections on Circulating Levels ofAlkaline Phosphatase in Hyp Mice

The X-linked Hyp mice harbors a large deletion in 3′ region of the PHEXgene and is the murine homologue of human X-linked hypophosphatemia(XLH). These mice therefore represent a useful model to study thepathophysiology of XLH as well as a to test the efficacy of therapeuticagents in preclinical studies.

The potential therapeutic effect of D₁₀sPHEX and sPHEX was thusinvestigated with bolus intravenous injection to Hyp/Y mice over a 2week period.

D₁₀sPHEX and sPHEX were dialyzed against vehicle and the solutions werefiltered through 0.22 μm low binding protein filter. The solutions werealiquoted and re-assayed for enzymatic activity and concentration byfluorogenic enzymatic assay and Bradford method, respectively.

Each mouse was anesthetized with vaporized Isoflurane (2%) and D₁₀sPHEX,or sPHEX were injected as an intravenous bolus through the subclavianvein. The dose was 5 mg/kg of body weight for each group. The animalswere treated once daily for 14 consecutive days. Blood samples (0.1-0.2ml) were collected via the subclavian vein under anesthesia on studydays-3 and +15 (before necropsy, 24 hours after last injection). TotalAlkaline phosphatase (ALP) levels were assayed in diluted serum (30 μlof serum sample with 90 μl of 0.9% saline USP). Although, appropriatedosages for human patients are not proportional to those used in mice,these dosages are predictive of the dosages ranges that could besuitable in humans using published tables.

As seen in FIG. 6 the D₁₀-extended form of sPHEX induced a largerdecrease in alkaline phosphatase levels than the normal sPHEX form.

Example 4 D₁₀ Fusion to Recombinant GST Increases its Binding to theMineral Phase of Bone In Vitro Fluorescein Labelling of PurifiedProteins

Recombinant purified proteins were labelled withfluorescein-isothiocyanate (FITC, Molecular Probes F143). Reaction wascarried out by adding proteins to 10 mM sodium phosphate, 50 mM NaClbuffer pH 7 at a final protein concentration of 1 mg/ml. Labellingreaction was started by adding FITC dissolved in DMSO at a concentrationof 20 mg/ml to reach 20:1 molar ratio with respect to the proteinconcentration. The mixture was left to react at room temperature for anhour. Labelled protein was separated from the free fluorescein on aPD-10™ column (Pharmacia) prior to dialysis in the binding buffer (1 mMsodium phosphate 150 mM NaCl, pH 7.4).

Preparation of the Mineral Phase of Bones

Long bones were dissected from a rat and crushed to powder in a liquidnitrogen cooled mortar. The powder was either kept at −80° C. ordirectly used. An aliquot of the powder (300 mg) was washed 3 times with8 ml of PBS and 8 ml of 1 M HCl were added. The mixture was kept insuspension on a rotating mixer for 1 hour at room temperature. Theinsoluble fraction was spun down and the clear acidic supernatantcollected. This acidic solution was stable at room temperature for atleast two weeks.

Binding Reaction

Aliquots of 20 μl of the acidic bone extract were mixed with 2 μl of 10M NaOH and the precipitate was pelleted 10,000×g for 3 minutes at roomtemperature. The pellet was rinsed twice by resuspending in 100 μl ofbinding buffer. The bone extract was then mixed with 100 μl of asolution containing 5 to 45 μg of fluorescein-labelled protein in thebinding buffer to which phosphate was added to reach a finalconcentration of 80 mM. The samples were incubated for 30 minutes atroom temperature on the rotating wheel to keep the mineral phase insuspension. The samples were then centrifuged for 3 minutes at roomtemperature. The pellet containing the bound protein was dissolved in200 μl of 0.5 M EDTA pH 8. To estimate the amount of free proteinpresent, 100 μl of 0.5 M EDTA pH 8 was added to the supernatant.Fluorescence of the different samples was measured on a 96 wells platereader set at 494 nm for excitation and 516 nm for emission.

Results

Samples containing 50 μg of fluorescein-labelled GST and GST-D₁₀ wereused in the binding assay described above. FIG. 9 A shows that fusion ofthe D₁₀ sequence to GST caused a 6-fold increase in binding to themineral phase of bone.

Example 5 D₁₀Fusion to sPHEX Increases its Binding to Bone

Using a procedure analogous to that described in Example 4 above,samples containing 50 μg of fluorescein-labelled sPHEX and D₁₀sPHEX wereused in a binding assay. FIG. 9 B shows that fusion of the D₁₀ sequenceto sPHEX caused a 4.3 increase in binding to the mineral phase of bone.

In contrast, D₆-sPHEX was constructed and tested after in vivo injectionin animals (as described in Example 1 above) and did not promote bindingof recombinant proteins to bone (Data not shown).

Example 6 D₁₀ Fusion to a Soluble Form of Alkaline Phosphatase Increasesits Targeting to the Mineral Phase of Bone

Construction of Expression Vectors Encoding Human Recombinant SolublePhosphatase Alkaline, sALP and sALP-D₃₀

The human full length cDNA encoding tissue non-specific alkalinephosphatase (ALP) was obtained from bone marrow polyA RNA (Clonetech) byRT-PCR. Briefly, 20 ng of polyA was reverse transcribed withSuperscriptII™ and an oligo dT₁₂₋₁₈ using the First Strand SynthesisSystem (Invitrogen). An aliquot representing 1/20^(th) of the RT stepwas used directly in a PCR reaction with ALP specific oligos (forward5′-gataaagcaggtcttggggtgcacc-3′ (SEQ ID NO: *); reverse5′-gttggcatctgtcacgggcttgtgg-3′ (SEQ ID NO: *)) and the Expand HighFidelity Enzyme Kit™ (Roche). The resulting ALP specific product (1644bp) was separated on and purified from an agarose gel (1%) using theQiaquick Gel Extraction Kit™ (QIAGEN). The ALP cDNA was then ligatedinto the pCR4-blunt-TOPO™ vector (Invitrogen), transformed into Top10™bacteria (Invitrogen), and a positive clone identified by colony PCR.The identity of the cDNA was verified by automated DNA sequencing.

Secreted forms of ALP (sALP) having the GPI anchor signal removed wereconstructed by PCR using Expand High Fidelity Enzyme Kit™ They comprisedresidues 1-502 followed by either a stop codon (sALP) or a decaaspartate targeting motif and a stop codon (sALP-D10). In both cases theforward primer (5′-tggatccaccatgatttcaccattcttagtac-3′ (SEQ ID NO: 40))covered the initiator methionine (underlined) and included a BamHI site(italicized). The reverse primers (sALP:5′-ttctagactacgagctggcaggagcacagtggccg-3′ (SEQ ID NO: 41); sALP-D₁₀6-ttctagactagtcgtcatcatcgtcatcatcgtcgtcatccgagctggcaggagoacagtggccg-3′(SEQ ID NO: 42)) contained a stop codon (underlined) and an XbaI site(italicized). The PCR products were digested with BamHI and XbaI andcloned into the pcDNA3.1-RSV that had been pre-digested with the sameenzymes. Plasmid DNA were sequenced.

ALP Fluorescent Enzymatic Assay

Enzymatic activity of sALP and sALP-D₁₀ was assayed using 4methylumbelliferyl phosphate (MUP, Molecular Probes, M8425) as afluorigenic substrate according to Gee K R et al. (Anal. Biochem. 273,41-48 (1999)) Typically, the assay was carried out at 37° C. in 96-wellplates in a final volume of 200 μl with 10 μM of MUP. Readings wererecorded using a Spectramax Gemini™ (Molecular Devices) plate readerevery minute for 30 minutes at 450 nm upon excitation at 360 nm.Emission wavelength cut-off was set at 435 nm. ALP initial speed ratewas estimated by linear regression fitting (with r² equal or greaterthan 0.98).

Expression of Recombinant sALP and sALP-D₁₀ Proteins

In order to determine whether the recombinant sALP and sALP-D₁₀ proteinswere secreted, each construct (pcDNA3-RSV-sALP-NEO andpcDNA3-RSV-sALP-D₁₀-NEO) was transiently transfected in HEK-293S cells(Human Embryonic Kidney cells; ATCC No. CRL-1392) using theLipofectamine-Plus liposome transfection kit™ (Invitrogen). HEK-293Scells were also mock-transfected as a negative control. The day aftertransfection, cells were incubated for 24 h in serum-free DMEM. Theconditioned media were collected and centrifuged at 14000 RPM for 5 minat 4° C. to remove dead cells and debris. The supernatants were assayedfor sALP or sALP-D₁₀ enzymatic activity and expression using the ALPfluorescent enzymatic assay and Western blotting respectively. ForWestern blotting, the spent media were precipitated for 1 h on ice withtrichloroacetic acid (final concentration 10% (v/v)). The precipitatedproteins were spun down at 14000 RPM for 20 min at 4° C., washed oncewith chilled acetone, dried, and resuspended in 60 μl 1× Laemmli samplebuffer with DTT and boiled for 5 min.

To evaluate the intracellular content of sALP and sALP-D₁₀ the cellswere washed 3 times with PBS and lysed with 200 μl Tris-HCl 50 mM (pH 8)containing 150 mM NaCl and 1% NP-40 on ice for 20 min. The lysates werespun down and the supernatant was assayed for sALP or sALP-D₁₀ enzymaticactivity and expression using the ALP fluorescent enzymatic assay andWestern blotting, respectively. For Western blotting, 50 μl aliquotswere mixed with 10 μl 6× Laemmli sample buffer with DTT and boiled for 5min.

Samples were loaded on a Novex Precast™ 4-12% Tris-Glycinepolyacrylamide gel (Invitrogen) and transferred onto 0.45 μmnitrocellulose (Protran, Schleicher&Schuell, Keene, N.H.) withTris-glycine containing 10% methanol. The membrane was stained withPonceau red and blocked for 1 h at room temperature with PBS containing0.05% Tween 20™ (PBST) and 5% dried milk. The membrane was thensequentially incubated at room temperature with the anti-hBAP antibody(mAb 4B-78, Developmental Studies Hybridoma Bank) (1:1000 in PBST with5% dried milk) and a rabbit anti-mouse IgG coupled to horseradishperoxidase (Sigma) (1:12000 in PBST with 5% dried milk). The signal wasdeveloped with the Western Lightning Chemiluminescence Reagent Plus™(PerkinElmer).

The ALP enzymatic activity measured in the conditioned media of HEK293after transient transfection was very high and of similar magnitude forpcDNA3-RSV-sALP-NEO (sALP) and pcDNA3-RSV-sALP-D₁₀-NEO (sALP-D₁₀) (FIG.13). This activity was specific to the plasmid DNA transfected as it wasundetectable in mock-transfected cells (mock). The relative activitymeasured in the media was 35-times greater than that measured in thecell extracts thus attesting to the secretory nature of sALP andsALP-D₁₀. Accordingly, for both sALP and sALP-D₁₀, immunoblotting usinga monoclonal antibody raised against recombinant tissue non-specifichuman alkaline phosphatase (mAb 4B-78, Developmental Studies HybridomaBank) revealed a much stronger signal in the conditioned media than inthe cell extracts (FIG. 14B, compare lanes 2, 3 vs. 5, 6). No signal wasvisualized in the mock-transfected samples (FIG. 14B, lanes 4 and 7).The signal appearing in the mock-transfected cells consists of BSAtrace. The apparent molecular weight of the protein detected wasestimated to be 70 kDa in the cell extracts (arrow) and slightly higherin the conditioned media (arrowhead). Ponceau red staining of themembrane was performed to monitor the uniform loading of samples (FIG.14A).

Generation of HEK293 Cells Constitutively Secreting sALP and sALP-D₁₀

To induce the stable expression of the sALP and sALP-D₁₀ proteins, thepcDNA3-RSV-sALP-NEO and pcDNA3-RSV-sALP-D₁₀-NEO vectors was transfectedseparately in HEK-293S cells using the Lipofectamine-Plus liposometransfection Kit™ (Invitrogen). Transfected cells were selected byadding 800 μg/ml G418 (Life Technologies) to the medium. For eachtransfection a pool of G-418 resistant cells were analyzed for sALP orsALP-D₁₀ expression in the spent culture media using the ALP fluorescentenzymatic assay. The conditioned media collected from the stable celllines were used for the binding assay study on the bone mineral.

Binding to Reconstituted Mineral Phase of Bone

Aliquots of 20 μl of the acidic bone extract were mixed with 2 μl of 10M NaOH and the precipitate was pelleted at 10,000×g for 3 minutes atroom temperature. The pellet was rinsed twice in 100 μl of buffer (1 mMsodium phosphate pH 7.4+150 mM NaCl). The resultant mineral phase ofbone (equivalent to 0.37 mg of dried powder) was then mixed with 100 μlof a solution containing sALP or sALP-D₁₀ proteins in the binding buffer(80 mM sodium phosphate pH 7.4+150 mM NaCl). The samples were incubatedfor 30 minutes at room temperature on the rotating wheel to keep themineral phase in suspension. The samples were then centrifuged for 3minutes at room temperature. The pellet containing the bound protein wasmixed with 180 μl of the ALP enzymatic assay buffer containing 0.1% BSAand the reaction initiated by adding 20 μl of 100 μM MUP. To allow formore homogeneous assay, conditions the 96 wells plate was shaken for 10seconds every minute for the duration of the assay.

Enzymatic activity retained on reconstituted mineral bone phase wascompared to the equivalent enzymatic activity added in the bindingassay. Values of 0.98% and 13.3% of total protein activity bound to thebone mineral phase were calculated for sALP and sALP-D₁₀ respectively. Abinding difference of more than 13 times in favour of sALP-D₁₀ suggeststhat the C-terminal fused deca-aspartate sequence directly targets sALPto the mineral phase of bone. Furthermore, the fact that it was possibleto measure directly ALP activity bound to the mineral phase of boneindicates that the enzyme is bound in a catalytically competent form tohydroxyapatite crystals.

Such fusion protein can be targeted directly to bones where theaccumulation of PPi inhibits skeletal mineralization.

Example 7 D₁₀-ALP Decreases Inhibitory Effect of Pyrophosphate on BoneMineralization

UMR106 cells were grown to confluence. They were then cultured for afurther 7 days in media containing 10 mM β-glycerophosphate to inducemineralization. Throughout this 7-day culture period, cells were treatedwith or without 75 μM pyrophosphate (PPi), a mineralization inhibitorand a alkaline phosphatase substrate. To assess the ability of alkalinephosphatase to rescue the PPi-induced mineralization inhibition, cellstreated with or without PPi were cultured with varying concentrations ofsemi-purified D₁₀-sALP produced from HEK293, human embryonic kidneycells. Mineralization was assessed by ⁴⁵Ca uptake. Parameters used forthis experiment are presented in table 2 below.

TABLE 2 PARAMETERS USED IN D₁₀-ALP ON PPI-INDUCED MINERALIZATIONINHIBITION [ALP] β-GP PPi ALP (Units/well) μl ALP/well (mM) (μM) — 0 010 0 — 0 0 10 75 D₁₀-sALP 1.5 0.5 10 0 D₁₀-sALP 1.5 0.5 10 75 D₁₀-sALP 31.0 10 0 D₁₀-sALP 3 1.0 10 75 D₁₀-sALP 4.5 1.5 10 0 D₁₀-sALP 4.5 1.5 1075 D₁₀-sALP 6 2 10 0 D₁₀-sALP 6 2 10 75

7-days of treatment with PPi resulted in a 43% decrease inmineralization. Co-treatment of cultures with D₁₀sALP resulted in adose-responsive rescue of this mineralization inhibition. Treatment with1.5 units of D₁₀-sALP resulted in a 30% decrease, 3 and 4.5 units a 24%decrease and 6 units resulted in a 15% decrease in mineralization,corresponding to a 65% rescue of PPi-induced mineralization inhibition.

These results show that the treatment of mineralizing osteoblast withD₁₀-sALP dose-responsively rescues mineralization inhibition induced byPPi.

The above Examples shows that a poly-aspartate fusion to recombinantproteins increases their binding to the mineral phase of bone or to bonetissue and increases the ability of the protein to perform itsbiological activity as compared to when it is administered alone.

Although the present invention has been described hereinabove by way ofpreferred embodiments thereof, it can be modified, without departingfrom the spirit and nature of the subject invention as defined in theappended claims.

REFERENCES

-   1—Weinberg, J M (2003) An overview of infliximab, etanercept,    efalizumab, and alefacept as biologic therapy for psoriasis. Clin    Ther 25: 2487-2505.-   2—Whyte M P, Valdes R Jr, Ryan L M, McAlister W H (1982) Infantile    hypophosphatasia: enzyme replacement therapy by intravenous infusion    of alkaline phosphatase-rich plasma from patients with Paget bone    disease. J Pediatr 101: 379-386.-   3—Whyte M P, Kurtzberg J, McAlister W H, Mumm S, Podgornik M N,    Coburn S, Ryan L M, Miller C R, Gottesman G S, Smith A K, Douville    J, Waters-Pick B, Armstrong R D, Martin P L (2003) Marrow cell    transplantation for infantile hypophosphatasia. J Bone Miner Res 18:    624-636.-   4—Fujisaki J, Tokunaga Y, Takahashi T, Shimojo F, Kimura S, Hata    T (1997) Osteotropic drug delivery system (ODDS) based on    biphosphonic prodrugs. IV: Effects of osteotropic estradiol on bone    mineral density and uterine weight in ovariectomized rats. J Drug    Targeting 5: 129-138.-   5—Uludag H, Gao T, Wohl G R, Kantoci D, Zernicke R F (2000) Bone    affinity of a biphosphonate-conjugated protein in vivo. Biotechnol    Prog 16: 1115-1118.-   6—Sekido T, Sakura N, Higashi Y, Miya K, Nitta Y, Nomura M,    Sawanishi H, Morito K, Masamune Y, Kasugai S, Yokogawa K, Miyamoto    K-I (2001) Novel drug delivery system to bone using acidic    oligopeptides: pharmacokinetic characteristics and pharmacological    potential. J Drug Targeting 9: 111-121.-   7—Hunter G K, Kyle C L, Goldberg H A (1994) Modulation of crystal    formation by bone phosphoproteins: structural specificity of the    osteopontin-mediated inhibition of hydroxyapatite formation. Biochem    J 300: 723-728.-   8—Rowe P S N, de Zoysa P A, Dong R, Wang H R, White K E, Econs M J,    Oudet C L (2000) MEPE, a new gene expressed in bone marrow and    tumors causing osteomalacia. Genomics 67: 54-68.-   9—Gilbert M, Shaw W J, Long J R, Nelson K, Drobny G P, Giachelli C    M, Stayton P S (2000) Chimeric peptides of statherin and osteopontin    that bind hydroxyapatite and mediate cell adhesion. J Biol Chem 275:    16213-16218.-   10-Young M F, Kerr J M, Ibaraki K, Heegaard A M, Robey P G (1992)    Structure, expression, and regulation of the major noncollagenous    matrix proteins of bones. Clin Orthop 281: 275-294.-   11-Salih E, Ashkar S, Gerstenfeld F C, Glimcher M J (1997)    Identification of the phosphorylated sites of metabollicaly    32P-labeled osteopontin from cultured chicken osteoblasts. J Biol    Chem 272: 13966-13973.-   12-Campbell P G, Andress D L (1997) Insulin-like growth factor    (IGF)-binding protein-5-(201-218) region regulates hydroxyapatite    and IGF-I binding. Am J Physiol 273: E1005-E1013.-   13-Patti J M, House-Pompeo K, Boles J O, Garza N, Gurusiddappa S,    Hook M (1995) Critical residues in the ligand-binding site of the    Staphylococcus aureus collagen-binding adhesin (MSCRAMM). J Biol    Chem 270: 12005-12011.-   14-Symersky J, Patti J M, Carson M, House-Pompeo K, Teale M, Moore    D, Jin L, Schneider A, DeLucas L J, Hook M, Narayana S V (1997)    Structure of the collagen-binding domain from a Staphylococcus    aureus adhesin. Nat Struct Biol 4: 833-838.

1-11. (canceled)
 12. A bone delivery conjugate comprising a structureselected from the group consisting of: A) X-D_(n)-Y-sALP-Z; and B)Z-sALP-Y-D_(n)-X, wherein X is absent or is an amino acid sequence of atleast one amino acid; Y is absent or is an amino acid sequence of atleast one amino acid; Z is absent or is an amino acid sequence of atleast one amino acid; D_(n) is a poly aspartate wherein n=10 to 16; andsaid sALP is a soluble alkaline phosphatase.
 13. The bone deliveryconjugate of claim 12, wherein said structure is: Z-sALP-Y-D_(n)-X. 14.The bone delivery conjugate of claim 13, wherein Y is an amino acidsequence of at least one amino acid and X and Z are absent.
 15. The bonedelivery conjugate of claim 14, wherein n=10.
 16. The bone deliveryconjugate of claim 13, wherein said sALP is a secreted soluble form ofsaid alkaline phosphatase.
 17. The bone delivery conjugate of claim 13,wherein said bone delivery conjugate is encoded by a nucleic acidmolecule which hybridizes under high stringency conditions to thecomplement of SEQ ID NO:
 7. 18. The bone delivery conjugate of claim 17,wherein said high stringency conditions comprise pre-hybridization andhybridization in 6×SSC, 5×Denhardt's reagent, 0.5% SDS and 100 mg/ml ofdenatured fragmented salmon sperm DNA at 68° C.; and washes in 2×SSC and0.5% SDS at room temperature for 10 minutes; in 2×SSC and 0.1% SDS atroom temperature for 10 minutes; and in 0.1×SSC and 0.5% SDS at 65° C.three times for five minutes.
 19. The bone delivery conjugate of claim18, wherein Y is an amino acid sequence of at least one amino acid and Xand Z are absent, and wherein n=10.
 20. A bone delivery compositioncomprising the bone delivery conjugate of claim 12 and apharmaceutically acceptable carrier.
 21. The bone delivery compositionof claim 20, wherein said structure is: Z-sALP-Y-D_(n)-X.
 22. The bonedelivery composition of claim 21, wherein said bone delivery conjugateis encoded by a nucleic acid molecule which hybridizes under highstringency conditions to the complement of SEQ ID NO: 7, wherein saidhigh stringency conditions comprise pre-hybridization and hybridizationin 6×SSC, 5×Denhardt's reagent, 0.5% SDS and 100 mg/ml of denaturedfragmented salmon sperm DNA at 68° C.; and washes in 2×SSC and 0.5% SDSat room temperature for 10 minutes; in 2×SSC and 0.1% SDS at roomtemperature for 10 minutes; and in 0.1×SSC and 0.5% SDS at 65° C. threetimes for five minutes.
 23. The bone delivery composition of claim 22,wherein Y is an amino acid sequence of at least one amino acid and X andZ are absent, and wherein n=10.
 24. A method of delivering a protein tobone tissue of a mammal comprising administering to said mammal aneffective amount of the bone delivery conjugate of claim
 12. 25. Themethod of claim 24, wherein said structure is: Z-sALP-Y-D_(n)-X; saidbone delivery conjugate is encoded by a nucleic acid molecule whichhybridizes under high stringency conditions to the complement of SEQ IDNO: 7; said high stringency conditions comprise pre-hybridization andhybridization in 6×SSC, 5×Denhardt's reagent, 0.5% SDS and 100 mg/ml ofdenatured fragmented salmon sperm DNA at 68° C.; and washes in 2×SSC and0.5% SDS at room temperature for 10 minutes; in 2×SSC and 0.1% SDS atroom temperature for 10 minutes; and in 0.1×SSC and 0.5% SDS at 65° C.three times for five minutes; Y is an amino acid sequence of at leastone amino acid and X and Z are absent; and n=10.
 26. The method of claim24, wherein said mammal is human.
 27. The method of claim 26, whereinsaid effective amount is 1 to 10 milligrams per kilogram of body weight.28. The method of claim 27, wherein said effective amount isadministered to said human more than once at an interval ranging fromdaily to weekly.
 29. The method of claim 26, wherein said effectiveamount is about 1 milligram per kilogram of body weight.
 30. A method oftreating a condition or disease related to a bone defect characterizedby a lack of or an insufficient amount of functional alkalinephosphatase comprising administering to a mammal in need thereof aneffective amount of the bone delivery conjugate of claim 12, wherein theconjugate is in a pharmaceutically acceptable carrier.
 31. The method ofclaim 30, wherein said condition or disease is hypophosphatasia.
 32. Themethod of claim 30, wherein said structure is: Z-sALP-Y-D_(n)-X; saidbone delivery conjugate is encoded by a nucleic acid molecule whichhybridizes under high stringency conditions to the complement of SEQ IDNO: 7; said high stringency conditions comprise pre-hybridization andhybridization in 6×SSC, 5×Denhardt's reagent, 0.5% SDS and 100 mg/ml ofdenatured fragmented salmon sperm DNA at 68° C.; and washes in 2×SSC and0.5% SDS at room temperature for 10 minutes; in 2×SSC and 0.1% SDS atroom temperature for 10 minutes; and in 0.1×SSC and 0.5% SDS at 65° C.three times for five minutes; Y is an amino acid sequence of at leastone amino acid and X and Z are absent; and n=10.
 33. The method of claim30, wherein said mammal is human.
 34. The method of claim 33, whereinsaid effective amount is 1 to 10 milligrams per kilogram of body weight.35. The method of claim 34, wherein said effective amount isadministered to said human more than once at an interval ranging fromdaily to weekly.
 36. The method of claim 33, wherein said effectiveamount is about 1 milligram per kilogram of body weight.